[Prevention and treatment of bacterial infection by the recombinant human granulocytic colony-stimulating factor in newborns].
An impact on the immune system is a principally new trend in optimizing the prevention and treatment of neonatal sepsis. The purpose of the case study was to investigate the clinical efficiency of neipogene. The study comprised 33 mature newborns with respiratory pathology and perinatal CNS lesion, who were at the artificial lung ventilation (ALV). Neipogene was found to increase for a short time period the absolute number of neutrophils, monocytes and the pool of stem cells (predecessors of the myeloid row) in peripheral blood, which cut the rate of sepsis, lethality, ALV time and treatment costs. The conclusion is that neipogene is safe and effective for the prevention and treatment of bacterial complications.
V V
VV
Estrin
E A
EA
Efanov
M G
MG
Pukhtinskaia
D015703:Antigens, CD / Q000097:blood; D001424:Bacterial Infections / Q000188:drug therapy* / Q000517:prevention & control; D001772:Blood Cell Count; D002493:Central Nervous System Diseases / Q000188:drug therapy / Q000517:prevention & control; D016179:Granulocyte Colony-Stimulating Factor / Q000191:economics / Q000627:therapeutic use*; D017048:Health Care Costs; D006801:Humans; D007231:Infant, Newborn; D008171:Lung Diseases / Q000188:drug therapy / Q000517:prevention & control; D011994:Recombinant Proteins
D015703:Antigens, CD; D011994:Recombinant Proteins; D016179:Granulocyte Colony-Stimulating Factor